Teva Unit Marketed Opioid For Off-Label Uses, Judge Hears

By Bonnie Eslinger (May 17, 2022, 11:42 PM EDT) -- Teva unit Cephalon saw sales of its opioid lollipop Actiq soar after it began marketing the product for non-FDA approved off-label uses, a judge heard Tuesday in recorded testimony from ex-Cephalon employees in a bellwether trial over claims the drugmaker and others illegally fueled San Francisco's opioid epidemic.

Stacey Beckhardt, who was a Cephalon public relations executive from 2001 to 2012, confirmed in her video-recorded deposition that the U.S. Food and Drug Administration had only approved Actiq for sudden increases or "breakthrough" pain related to cancer, so the painkiller couldn't be marketed for other uses.

But a lawyer for the city...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!